Trial Profile

A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NPX 372 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors NextPoint Therapeutics

Most Recent Events

08 Sep 2026 Status changed from not yet recruiting to recruiting.
06 May 2026 Status changed from planning to not yet recruiting.
09 Feb 2026 According to NextPoint Therapeutics media release, the IND for the clinical development of NPX-372 has been cleared by the USFDA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com